Results 221 to 230 of about 350,390 (302)
Remdesivir in COVID-19: A Focus on Pediatric Cardiac Patients. [PDF]
Bsat D, Safi D, Arabi M.
europepmc +1 more source
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale +5 more
wiley +1 more source
Identifying high-risk combinations of metformin during COVID-19. [PDF]
Dimnjaković J +5 more
europepmc +1 more source
Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel +12 more
wiley +1 more source
Evaluation of artificial intelligence identified ipratropium bromide for the treatment of coronavirus disease 2019. [PDF]
Jung DS +11 more
europepmc +1 more source
Aim Hyponatremia is a common yet potentially serious adverse event associated with antidepressants. Identifying the antidepressant class with the least risk of hyponatremia would improve patient safety. Methods Using electronic medical records from 15 hospitals standardized into Observational Medical Outcomes Partnership Common Data Model (2003–2023 ...
Kyungyeon Jung +21 more
wiley +1 more source
Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease. [PDF]
Abdelghany M, Yu F, Rennard S, Gwon Y.
europepmc +1 more source
Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All
Arthritis &Rheumatology, EarlyView.
Stephen J. Balevic +2 more
wiley +1 more source
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola +5 more
wiley +1 more source

